BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq
Executive Summary
Analysts say black box warning of anaphylaxis risk and REMS were anticipated. Company plans a gradual rollout of Palynziq, focusing first on Phase III clinical trial sites and patients.
You may also be interested in...
PTC Eyes Transition From Capital-Raising To Money-Making Company
With $1.1bn in cash plus revenue from its existing commercial products and royalties from Roche’s sales of newly approved Evrysdi to invest in R&D, PTC Therapeutics may achieve profitability in 2023.
2018 Saw Record Launches, But No Big Splash
The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.
Risankizumab, Andexanet Alfa & GSK’s IV Zanamivir Up For CHMP Opinion
Opinions on whether new products for the treatment of conditions such as psoriasis, coagulation reversal, flu and diabetes should be granted an EU marketing authorization are due this week as the EMA’s key scientific committee, the CHMP, meets for the last time in London..